Navigation Links
Nile Therapeutics Announces Information in Compliance With NASDAQ Marketplace Rule 4350 and Reiterates 2009 Objectives
Date:3/18/2009

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a leading company in the development of novel therapeutics for heart failure patients, today announced that, pursuant to Nasdaq Marketplace Rule 4350(b)(1)(B), its audited financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K, filed on March 12, 2009, contained a going concern qualification from its independent registered public accounting firm, Hays & Company LLP.

This announcement is required by Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion containing a going concern qualification. This announcement does not represent any change or amendment to the company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2008.

2009 Objectives

Nile is focused on very specific clinical and corporate objectives:

  • To complete the dosing of a 30 patient, placebo-controlled Phase 2b study in the 3rd quarter of 2009. This study is designed to provide additional clinical evidence that CD-NP enhances renal function. This finding would favorably differentiate CD-NP from other acute heart failure therapies.
  • Through financing, partnering or other strategic alternative, secure the resources necessary to continue development activities beyond the 30 patient Phase 2b study.
  • To start enrollment into the 330 patient double-blind, placebo-controlled Phase 2b acute heart failure Proof of Concept study.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Medarex to Present at the Needham Cancer Therapeutics Conference
2. Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
(Date:12/15/2014)... -- GlassesOff Inc. (OTCBB: GLSO) announced today the appointment of ... of the Company,s Board of Directors. Mr. ... CEO until its acquisition by Stanley Black ... as the inventor of the first Wi-Fi-based Active RFID ... RFID solutions focused on improving operational efficiency, safety and ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma A/S, ... technology to address significant unmet medical needs, today ... Phase 2 pediatric study to evaluate once-weekly TransCon ... or GHD.  This interim analysis consists of 25 ... enrollment in the study, completing all six months ...
(Date:12/13/2014)... /CNW/ - MaRS and Virgin Unite Canada, the non-profit foundation ... forces to support Canadian entrepreneurs tackling social and environmental challenges. ... at the MaRS Centre to announce the new partnership, which ... This fund has $1 million in seed capital provided by ... Mindset Social Innovation Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
... SeqWright Inc., a world-wide leader in custom genomic ... strides to position itself as the Next-Generation Sequencing ... can be attributed to the company,s ability to ... in key genomics technologies. Building on this success, ...
... 11, 2011 Regenicin, Inc. (OTC Bulletin Board: ... development of regenerative cell therapies to restore the health ... 4th annual OneMedForum at the Sir Francis Drake Hotel ... Randall McCoy, will present Regenicin,s core business model and ...
... 2011 AstraZeneca (NYSE: AZN ) and ... advancing therapies for cancer patients through clinical research, today ... a novel targeted oncology compound from AstraZeneca. ... accounting for 7.4 million (or 13%) of all deaths ...
Cached Biology Technology:SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 3
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/18/2014)... , Nov. 18, 2014  The Secure Identity ... Association today jointly announce the formation of The ... of its Identity and Biometric Entry and ... Framework received official support from BORDERPOL, the international ... improve and provide expertise regarding border security, traveler ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... recent surge of DNA sequence information resulting from deciphering ... for innovative technological developments that have been vital in ... has allowed for the development of novel genetic therapies ... The new genomic era heralds earlier diagnoses, greatly ...
... fluorescence is an effective way of determining how ... technique described in the open access journal ... a quantitative and precise determination of viability in ... demands of industrial, municipal and agricultural consumption on ...
... widespread in the animal kingdom than previously thought. A ... fiddler crabs "lie" about their fighting ability by growing ... fact weak and puny. Published this week in the ... study is the first direct evidence that crabs "bluff" ...
Cached Biology News:Personalized medicine: Innovative online journal leads the way 2Fiddler crabs reveal honesty is not always the best policy 2Fiddler crabs reveal honesty is not always the best policy 3
... for western blots ,• Optically clear plastic ... staining western blots. The reduced size (60 ... disposable tray requires less dye and antibodies ... the user. Pour spouts in each corner ...
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... Qentix Western Blot Signal Enhancer does for enzyme-/substrate-based ... it increases the signal up to 10-fold ... minutes., ,The Western Blot Signal Enhancer membrane ... be added to your current Western blotting ...
... Solid phase extraction through columns is ... range of applications. Typical applications are in ... in diagnostics, or compound purification in chemical ... fully automated on the Genesis series instruments ...
Biology Products: